Cerebrolysin vs Dihexa
Both Cerebrolysin and Dihexa are used for cognitive and neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
Cerebrolysin
Evidence BCerebrolysin (porcine brain peptide complex)
A standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.
View full Cerebrolysin profile →Dihexa
Evidence CDihexa (PNB-0408)
An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.
View full Dihexa profile →Side-by-Side
| Attribute | Cerebrolysin | Dihexa |
|---|---|---|
| Evidence Grade | B | C |
| FDA Status | Not FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementia | Not FDA-approved — research compound (HGF/c-Met-mimetic) |
| Typical Dose | Trial range: 5–30 mL daily (intravenous infusion) | 8–45 mg orally daily (research-only) |
| Clinics Indexed | 41 | 10 |
| Categories | cognitive, neuroprotection | cognitive, neuroprotection |
Key reported benefits — Cerebrolysin
- ✓Stroke recovery support
- ✓TBI rehabilitation
- ✓Cognitive function in dementia
Key reported benefits — Dihexa
- ✓Synaptogenesis (preclinical)
- ✓Memory improvement (animal)
- ✓Possible Alzheimer's relevance
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.